Issue 12, 2019

Design of a MUC1-based tricomponent vaccine adjuvanted with FSL-1 for cancer immunotherapy

Abstract

MUC1 is an attractive target for cancer vaccines as a result of its over-expression and aberrant glycosylation pattern on many tumor cells. However, the low immunogenicity of MUC1 and immune tolerance have limited its application. Herein, we designed MUC1-based tricomponent antitumor vaccines adjuvanted with fibroblast stimulating lipopeptide 1 (FSL-1). Immunological results indicate that the glycosylated tricomponent vaccine candidate has elicited both humoral and cellular immune responses. The induced antibodies could effectively bind to MCF-7. Furthermore, the vaccine exhibited an obvious reduction in tumour burden.

Graphical abstract: Design of a MUC1-based tricomponent vaccine adjuvanted with FSL-1 for cancer immunotherapy

Supplementary files

Article information

Article type
Research Article
Submitted
03 May 2019
Accepted
10 Jul 2019
First published
12 Jul 2019

Med. Chem. Commun., 2019,10, 2073-2077

Design of a MUC1-based tricomponent vaccine adjuvanted with FSL-1 for cancer immunotherapy

M. Li, Z. Wang, B. Yan, X. Yin, Y. Zhao, F. Yu, M. Meng, Y. Liu and W. Zhao, Med. Chem. Commun., 2019, 10, 2073 DOI: 10.1039/C9MD00254E

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements